Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease

Documents similaires

• Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD
  par: Mary Sano, et autres
  Publié: (2024)
• Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease
  par: Wiesje M. van der Flier, et autres
  Publié: (2024)
• Comparison of eligibility criteria and baseline characteristics between the patient populations of evoke and evoke+, Clarity AD, and TRAILBLAZER‐ALZ‐2
  par: Howard H. Feldman, et autres
  Publié: (2024)
• Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease
  par: Garrett R. Mullins, et autres
  Publié: (2025)
• Infusion‐related reactions in donanemab‐treated participants with early symptomatic Alzheimer's disease
  par: Paul Ardayfio, et autres
  Publié: (2026)